PP.42 Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC

Concurrent blockade of LAG-3 may enhance efficacy of anti–programmed cell death-1 (anti–PD-1) therapies. We presented safety and clinical activity data from a Phase 1 study in patients with NSCLC treated with anti–LAG-3 (fianlimab) + anti–PD-1 (cemiplimab). This work is an adaption of the abstract submitted at ESMO Immuno-Oncology Congress 2022.